
Aptevo Therapeutics Inc APVO.OQ APVO.O is expected to show no change in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Aptevo Therapeutics Inc is for a loss of $4.21 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aptevo Therapeutics Inc is $21.00, above its last closing price of $0.50.
This summary was machine generated May 2 at 14:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)